
SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00.
Shares of Blueprint Medicines are trading down 8.32% over the last 24 hours, at $44.07 per share.

SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00.
Shares of Blueprint Medicines are trading down 8.32% over the last 24 hours, at $44.07 per share.